Home › Scleroderma
Scleroderma clinical trials recruiting in the U.S.
33 studies for Scleroderma are recruiting participants at sites across the United States.
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
Cities with the most studies
- New York City, NY11 studies
- Chicago, IL10 studies
- Ann Arbor, MI10 studies
- Houston, TX9 studies
- Los Angeles, CA7 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- New Orleans, LA6 studies
- Pittsburgh, PA5 studies
- Dallas, TX5 studies
- Washington, DC4 studies
- Edison, NJ4 studies
- Charleston, SC4 studies
- Kansas City, KS4 studies
- Phoenix, AZ4 studies
- Plantation, FL4 studies
- Miami, FL4 studies
- New Haven, CT4 studies
- Mountain View, CA3 studies
- Jacksonville, FL3 studies
- Aurora, CO3 studies
- Cedar Rapids, IA3 studies
- Charlotte, NC3 studies
- Tucson, AZ3 studies
- St. Louis, MO3 studies
- San Diego, CA3 studies
- Minneapolis, MN3 studies
By state
- Alabama3 studies
- Arizona6 studies
- California13 studies
- Colorado4 studies
- Connecticut4 studies
- District of Columbia4 studies
- Florida9 studies
- Illinois11 studies
- Iowa3 studies
- Kansas5 studies
- Kentucky3 studies
- Louisiana6 studies
- Maryland6 studies
- Massachusetts7 studies
- Michigan10 studies
- Minnesota5 studies
- Missouri3 studies
- New Jersey5 studies
- New York11 studies
- North Carolina9 studies
- Ohio4 studies
- Pennsylvania10 studies
- South Carolina4 studies
- Tennessee5 studies
- Texas12 studies
- Virginia3 studies
Recently updated studies
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07497087A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717FT839 in Autoimmune Diseases
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 2, 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RecruitingPhase 2
Ages 8 to 60 · All sexes · Updated Aug 14, 2026 · NCT03630211A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07295847Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07090226A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06827977Systemic Sclerosis DIet for GastrointESTinal Symptoms
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT07402226US Zamto-cel Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06708845A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
RecruitingObservational studyHealthy volunteers welcome
Up to age 90 · All sexes · Updated May 12, 2026 · NCT01808937Intralesional Injection of STS in Treatment of Calcinosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06672822Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06434363A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07047690Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 27, 2026 · NCT03844061Open Label Treprostinil Raynaud's Study
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 24, 2026 · NCT07112183From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.